AP-01 / Apmonia Therap - LARVOL DELTA

Remodeling the Tumor Microenvironment through TSP-1/CD47 Antagonization: Non-Clinical Characterization of the TAX2 drug candidate (EACR 2025) - "TAX2 peptide, a first-in-class TSP-1/CD47 antagonist, is being developed as an injectable product for the treatment of cancers. These non-clinical data support this concept and TAX2 is now expected to enter in Phase 1/2a clinical trial in advanced solid tumors."

Biomarker • Clinical • Tumor microenvironment • Oncology • Ovarian Cancer • Solid Tumor • SIRPA

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research. (PubMed, Mol Cancer) - "Our study thus (1) proposes a CD47-based stratification of patients who may be most likely to benefit from postoperative immunotherapy, and (2) suggests that TAX2 is a potential alternative therapy for patients relapsing on PARP inhibitors."

Biomarker • IO biomarker • Journal • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • CD47 • CD8

Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi). (ASCO 2024) - P2 | "To assess the efficacy of TAX2 and/or PARPi (olaparib) treatment, we used ID8 cells harboring Trp53 -/- and Brca2 -/- mutations, as a pertinent syngeneic representation of intraperitoneal high-grade serous TP53 and BRCA2 mutated OC. Our findings propose TAX2 as a promising strategy for patients relapsing on PARP inhibitors. TAX2 displayed a selective biodistribution pattern in mice, concentrating at tumor sites. Our study showcased that while TAX2 alone exhibited significant but modest activity in PARPi-naive mice, its efficacy significantly increased post-PARPi exposure, irrespective of PARPi duration."

Clinical • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA2 • SIRPA